The RIALTO trial of pediatric patients with CD19-positive r/r BCP-ALL demonstrated that children who reached complete remission after at least two blinatumomab cycles and proceeded to HSCT showed improved outcomes when compared to those who did not receive blinatumomab [8]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.